Literature DB >> 25682331

Arthroscopic Anatomy of the Dislocated Hip in Infants and Obstacles Preventing Reduction.

Oliver Eberhardt1, Thomas Wirth2, Francisco F Fernandez2.   

Abstract

PURPOSE: The purpose of this study was to describe the anatomy as seen arthroscopically, the role of the labrum and its relevance in luxation and reduction procedures, and secondary changes to the cartilaginous acetabular roof and to determine the main obstacles preventing reduction of dislocated hips in infants and young children.
METHODS: A specialized pediatric medial approach to hip arthroscopy was performed on 25 hip joints in 21 patients younger than 4 years of age. The arthroscopic procedure was conducted using a 2.7-mm cannulated instrument. A subadductor portal was used for the 70° arthroscope, and a high anterolateral portal served as a working portal. The anatomic findings of the individual hip joints were recorded. We examined the femoral head, the teres ligament, the transverse ligament, the acetabulum, and the acetabular labrum. The obstacles preventing reduction were successively resected.
RESULTS: An arthroscopic investigation of all major structures and arthroscopic reduction was possible in 25 hip joints. A hypertrophic teres ligament was present in 23 of the 25 hips. Capsular constriction prevented reduction in 22 of the 25 hips. The acetabular labrum was not inverted in any of the examined hip joints and was also never an obstacle to reduction. Secondary changes to the cartilaginous preformed acetabular roof were present in 10 hips.
CONCLUSIONS: We have shown that arthroscopy of a developmentally dislocated hip can be safely performed using the subadductor portal. Through this arthroscopic approach, we were able to identify the previously described pathologic structures-the limbus, neolimbus, pulvinar, hypertrophic teres ligament, and capsular constriction. The capsule was the most common block to reduction, followed by the teres ligament. Successful reduction can be achieved by removal of intra-articular tissues, the pulvinar, and the teres ligament, and nearly always a capsular release. The limbus and neolimbus were not factors in achieving reduction in our series. LEVEL OF EVIDENCE: Level IV, case series.
Copyright © 2015 Arthroscopy Association of North America. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25682331     DOI: 10.1016/j.arthro.2014.12.019

Source DB:  PubMed          Journal:  Arthroscopy        ISSN: 0749-8063            Impact factor:   4.772


  6 in total

Review 1.  [Hip dysplasia-new and proven methods].

Authors:  Oliver Eberhardt; T Wirth
Journal:  Orthopade       Date:  2019-06       Impact factor: 1.087

2.  Serum prolidase activity and oxidative-antioxidative status in patients with developmental dysplasia of the hip and its relationship with radiographic severity.

Authors:  Mehmet Akif Altay; Cemil Ertürk; Ali Levent; Baki Volkan Çetin; Nurten Aksoy
Journal:  Redox Rep       Date:  2016-06-20       Impact factor: 4.412

3.  Arthroscopic versus open, medial approach, surgical reduction for developmental dysplasia of the hip in patients under 18 months of age.

Authors:  Serda Duman; Yalkin Camurcu; Hakan Sofu; Hanifi Ucpunar; Deniz Akbulut; Timur Yildirim
Journal:  Acta Orthop       Date:  2019-04-02       Impact factor: 3.717

4.  Comparison of arthroscopic and open reduction of conservatively irreducible dislocated hips of children.

Authors:  C Presch; O Eberhardt; T Wirth; F F Fernandez
Journal:  J Child Orthop       Date:  2019-08-01       Impact factor: 1.548

5.  A Single Approach to Arthroscopic Reduction and Debridement for Developmental Dislocation of the Hip in 12 Infants.

Authors:  Chao Feng; Xue-Min Lv; Shi-Qi Wan; Yuan Guo
Journal:  Med Sci Monit       Date:  2019-11-21

6.  The limbus in developmental dysplasia of the hip: An obstacle to reduction and its images changed by the femoral head position.

Authors:  Soon Hyuck Lee; Kyung-Sik Ahn; Hae Woon Jung; Woo Young Jang
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.